switching from glp 1 to tirzepatide between GLP‐1 receptor agonists in clinical practice: Expert consensus and practical guidance Pharmacogenomics of Tirzepatide: Genomic Insights

The medication is administered through a convenient once-weekly subcutaneous injection, improving adherence and making it easier for our patients to incorporate into their routines

In May, Australia banned compounded GLP-1s citing safety concerns

As it was a Korea-customized clinical trial, the company set the obesity standard to suit the domestic guideline of BMI 25kg/

Signs of dehydration include decreased urination, dark-colored urine, dizziness when standing, dry mouth, and increased thirst

Consistent, gradual weight loss like 30 lbs over nine months is typically a strong response to these medications if combined with diet and lifestyle tweaks